Institutions / International Biotechnology Trust PLC
International Biotechnology Trust PLC
CIK 942257 · Institution · as of Sep 30, 2023
Portfolio value
$296.85M
Positions
65
As of
Sep 30, 2023
Portfolio trend
Portfolio value
$296.85M-9.6%Positions
65+6.6%Top holdings
Sep 30, 2023View all 65 →
| Company | Value | % of portfolio |
|---|---|---|
| Amgen IncAMGN | $21.30M | 7.2% |
| Incyte CorpINCY | $20.70M | 7.0% |
| Gilead Sciences IncGILD | $17.51M | 5.9% |
| Intra-Cellular Therapies, Inc.ITCI | $16.55M | 5.6% |
| Biomarin Pharmaceutical IncBMRN | $13.60M | 4.6% |
| Supernus Pharmaceuticals IncSUPN | $11.75M | 4.0% |
| Vera Therapeutics, Inc.VERA | $10.38M | 3.5% |
| Biogen Inc.BIIB | $10.33M | 3.5% |
| Harmony Biosciences Holdings, Inc.HRMY | $10.31M | 3.5% |
| Mirati Therapeutics Inc C | $9.40M | 3.2% |
| Ultragenyx Pharmaceutical Inc.RARE | $8.91M | 3.0% |
| uniQure N.V.QURE | $8.33M | 2.8% |
| Aurinia Pharmaceuticals Inc.AUPH | $8.07M | 2.7% |
| UNITED THERAPEUTICS CorpUTHR | $7.66M | 2.6% |
| Vertex Pharmaceuticals Inc / MaVRTX | $7.30M | 2.5% |
| Regeneron Pharmaceuticals IncREGN | $7.28M | 2.5% |
| Illumina IncILMN | $6.93M | 2.3% |
| Alnylam Pharmaceuticals, Inc.ALNY | $6.52M | 2.2% |
| Amylyx Pharmaceuticals, Inc.AMLX | $5.40M | 1.8% |
| Krystal Biotech, Inc.KRYS | $5.34M | 1.8% |
| Karuna Therapeutics Inc C | $5.16M | 1.7% |
| Axsome Therapeutics, Inc.AXSM | $4.07M | 1.4% |
| Erasca, Inc.ERAS | $3.79M | 1.3% |
| Acadia Pharmaceuticals IncACAD | $3.74M | 1.3% |
| Revance Therapeutics, Inc.RVNC | $3.31M | 1.1% |
Activity
Sep 30, 2023View full history →
InsidersInstitutions
This fund's quarter-over-quarter position changes — what it's buying and selling.| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q2 2022 as of | Trim Other (per filing) | Dyne Therapeutics, Inc. common | $-68.72B | -472K -99.19% | 3,865 189.52% of portfolio | high |
| Q2 2022 as of | Trim Other (per filing) | M47364100 | $-61.12B | -107K -99.83% | 187 36.05% of portfolio | high |
| Q2 2022 as of | Trim Other (per filing) | AUPH Aurinia Pharmaceuticals Inc. common | $-42.75B | -429K -98.68% | 5,758 193.21% of portfolio | high |
| Q2 2022 as of |